

ARGENICA APPOINTS VICE PRESIDENT OF PRODUCT DEVELOPMENT

Perth, Australia; 7 OCTOBER 2024 – Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is pleased to announce it has appointed Dr Stuart Gribble as Vice President of Product Development. Stuart will lead Argenica’s product development activities, including new formulation development, manufacturing and preclinical and clinical development of indications outside of acute ischaemic stroke, whilst working with our existing clinical trial team to provide support on our stroke trial as required.

Stuart is a highly experienced biotechnology executive with an extensive background in drug development across large pharmaceutical companies and ASX listed biotechnology companies. With over 25 years of proven success in leading product development multi-national project teams to evaluate, plan and execute complex product development programs from laboratory to global commercialization, Stuart will provide support across all areas of Argenica’s drug development program. Stuart holds a PhD in Neuroscience from the University of Melbourne, and a Bachelor of Science (Honours) from Monash University.

Stuart is joining Argenica from Telix Pharmaceuticals (ASX:TLX) where he was the Vice President of the CAIX Program since January 2019, successfully leading clinical trial programs and engagement with regulatory authorities, including the US Food & Drug Administration, to commercialise Telix’s radiopharmaceuticals. Prior to joining Telix, Stuart worked at CSL and Pfizer in a variety of product and research development roles.

Dr Liz Dallimore, **Argenica’s Managing Director**, said: “We are delighted to have Stuart join Argenica as our Vice President of Product Development. Stuart brings over 25 years of experience working in drug development, taking products from the lab through early and late-stage clinical trials, and into the market. His skill set is the perfect complement to our existing team as we progress through our Phase 2 clinical trial in stroke and continue to generate exciting data in our other neurology indications.”

Stuart commenced with the Company on 7 October 2024 in a full-time capacity.

This announcement has been approved for release by the Managing Director and Company Secretary.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has now initiated a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.